A large study of the Novartis drug letrozole, marketed as Femara, shows it is more useful than tamoxifen for treating women at risk of having breast cancer return. The two drugs were compared in a study of 8,000 women, and those women whose breast cancer had spread to their lymph nodes experienced 29% fewer cases of their cancer returning when treated with letrozole.

Related Summaries